BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Review of Anticancer Therapy 2014;7:169-81. [DOI: 10.1586/14737140.7.2.169] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Wang D, Fang X. In Vitro Generation of Anti-Osteosarcoma Cytotoxic Activity Using Dendritic Cells Loaded with Heat Shock Protein 70-Peptide Complexes. Fetal Pediatr Pathol 2019;38:387-98. [PMID: 30955440 DOI: 10.1080/15513815.2019.1600624] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Park SH, Lee J, Kang MA, Jang KY, Kim JR. Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. Oncol Lett 2018;15:9687-96. [PMID: 29928344 DOI: 10.3892/ol.2018.8547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sun X, Niu G, Yan Y, Yang M, Chen K, Ma Y, Chan N, Shen B, Chen X. Phage display-derived peptides for osteosarcoma imaging. Clin Cancer Res 2010;16:4268-77. [PMID: 20570932 DOI: 10.1158/1078-0432.CCR-10-0968] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
4 Xu J, Xu G, Zhang T, Chen T, Zhao W, Wang G. NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression. Biomed Res Int 2019;2019:4068521. [PMID: 31886210 DOI: 10.1155/2019/4068521] [Reference Citation Analysis]
5 Serrano MC, Portolés MT, Pagani R, de Guinoa JS, Ruiz-hernández E, Arcos D, Vallet-regí M. In Vitro Positive Biocompatibility Evaluation of Glass–Glass Ceramic Thermoseeds for Hyperthermic Treatment of Bone Tumors. Tissue Engineering Part A 2008;14:617-27. [DOI: 10.1089/tea.2007.0205] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
6 Moukengue B, Brown HK, Charrier C, Battaglia S, Baud'huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. EBioMedicine 2020;53:102704. [PMID: 32151797 DOI: 10.1016/j.ebiom.2020.102704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 2013;5:591-616. [PMID: 24216993 DOI: 10.3390/cancers5020591] [Cited by in Crossref: 131] [Cited by in F6Publishing: 124] [Article Influence: 14.6] [Reference Citation Analysis]
8 Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX, Miao DS, De W. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009;327:257-66. [PMID: 19229591 DOI: 10.1007/s11010-009-0064-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
9 Mccoy TH, Kim HJ, Cross MB, Fragomen AT, Healey JH, Athanasian EA, Rozbruch SR. Bone tumor reconstruction with the Ilizarov method: Ilizarov Reconstruction of Bone Tumors. J Surg Oncol 2013;107:343-52. [DOI: 10.1002/jso.23217] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
10 Arcos D, Vallet-regí M. Bioceramics for drug delivery. Acta Materialia 2013;61:890-911. [DOI: 10.1016/j.actamat.2012.10.039] [Cited by in Crossref: 186] [Cited by in F6Publishing: 98] [Article Influence: 20.7] [Reference Citation Analysis]
11 Li Y, Bäckesjö CM, Haldosén LA, Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol 2009;609:13-8. [PMID: 19285066 DOI: 10.1016/j.ejphar.2009.03.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
12 Zou J, Zhang W, Li XL. Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway. Calcif Tissue Int 2017;100:551-64. [PMID: 28246931 DOI: 10.1007/s00223-016-0231-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Yang H, Peng Z, Liang M, Zhang Y, Wang Y, Huang T, Jiang Y, Jiang B, Wang Y. The miR-17-92 cluster/QKI2/β-catenin axis promotes osteosarcoma progression. Oncotarget 2018;9:25285-93. [PMID: 29861871 DOI: 10.18632/oncotarget.23935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sakamoto A, Yamashita M, Hori Y, Okamoto T, Shimizu A, Matsuda S. Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis. Am J Case Rep 2017;18:1130-4. [PMID: 29061956 DOI: 10.12659/ajcr.905637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
15 Castro-gamero AM, Borges KS, da Silva Silveira V, Lira RCP, de Paula Gomes Queiroz R, Valera FCP, Scrideli CA, Umezawa K, Tone LG. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anti-Cancer Drugs 2012;23:638-50. [DOI: 10.1097/cad.0b013e328350e835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Toledo SR, Oliveira ID, Okamoto OK, Zago MA, de Seixas Alves MT, Filho RJ, Macedo CR, Petrilli AS. Bone deposition, bone resorption, and osteosarcoma. J Orthop Res 2010;28:1142-8. [PMID: 20225287 DOI: 10.1002/jor.21120] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
17 Singh R, Srivastava M, Prasad NK, Awasthi S, Kumar Dhayalan A, Kannan S. Structural analysis and magnetic induced hyperthermia of Fe 3+ and Mn 2+ substituted β-Ca 3 (PO 4 ) 2. New J Chem 2017;41:12879-91. [DOI: 10.1039/c7nj01228d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
18 Zhang R, Lu M, Zhang Z, Tian X, Wang S, Lv D. Resveratrol reverses P-glycoprotein-mediated multidrug resistance of U2OS/ADR cells by suppressing the activation of the NF-κB and p38 MAPK signaling pathways. Oncol Lett 2016;12:4147-54. [PMID: 27895784 DOI: 10.3892/ol.2016.5136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
19 Lockwood WW, Stack D, Morris T, Grehan D, O'Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM, O'Sullivan MJ. Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn 2011;13:289-96. [PMID: 21458381 DOI: 10.1016/j.jmoldx.2010.11.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
20 Xiao X, Wang W, Wang Z. The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma. Pediatr Drugs 2014;16:503-12. [DOI: 10.1007/s40272-014-0095-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
21 Clézardin P. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. Bull Cancer 2011;98:837-46. [PMID: 21700551 DOI: 10.1684/bdc.2011.1398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
22 Alcaide M, Ramírez-santillán C, Feito MJ, de la Concepción Matesanz M, Ruiz-hernández E, Arcos D, Vallet-regí M, Portolés MT. In vitro evaluation of glass-glass ceramic thermoseed-induced hyperthermia on human osteosarcoma cell line. J Biomed Mater Res 2012;100A:64-71. [DOI: 10.1002/jbm.a.33229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
23 Xu T, Jiang W, Fan L, Gao Q, Li G. Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21. Oncotarget 2017;8:101406-17. [PMID: 29254174 DOI: 10.18632/oncotarget.20738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
24 Zhao J, Xu H, He M, Wu Y. Glucocorticoid receptor DNA binding factor 1 expression and osteosarcoma prognosis. Tumour Biol 2014;35:12449-58. [PMID: 25185653 DOI: 10.1007/s13277-014-2563-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
25 Singh RK, Srivastava M, Prasad NK, Shetty PH, Kannan S. Hyperthermia effect and antibacterial efficacy of Fe 3+ /Co 2+ co‐substitutions in β‐Ca 3 (PO 4 ) 2 for bone cancer and defect therapy. J Biomed Mater Res 2018;106:1317-28. [DOI: 10.1002/jbm.b.33921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
26 Xie D, Zheng GZ, Xie P, Zhang QH, Lin FX, Chang B, Hu QX, Du SX, Li XD. Antitumor activity of resveratrol against human osteosarcoma cells: a key role of Cx43 and Wnt/β-catenin signaling pathway. Oncotarget 2017;8:111419-32. [PMID: 29340064 DOI: 10.18632/oncotarget.22810] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
27 Yu X, Wang Q, Zhou X, Fu C, Cheng M, Guo R, Liu H, Zhang B, Dai M. Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-κB signaling pathway in vitro. Oncol Lett 2016;12:3423-8. [PMID: 27900015 DOI: 10.3892/ol.2016.5049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
28 Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012;2:19. [PMID: 23036272 DOI: 10.1186/2045-3329-2-19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
29 Brand RA. 50 years ago in CORR: the present trend in treatment of osteogenic sarcoma. Clin Orthop Relat Res 2009;467:3038-9. [PMID: 19701673 DOI: 10.1007/s11999-009-1051-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
30 Zou J, Gan M, Mao N, Zhu X, Shi Q, Yang H. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Arch Med Res 2010;41:162-9. [PMID: 20682173 DOI: 10.1016/j.arcmed.2010.04.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
31 Battaglia S, Dumoucel S, Chesneau J, Heymann MF, Picarda G, Gouin F, Corradini N, Heymann D, Redini F. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res 2011;26:2439-51. [PMID: 21713986 DOI: 10.1002/jbmr.453] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
32 Xiao X, Wang W, Zhang H, Gao P, Fan B, Huang C, Fu J, Chen G, Shi L, Zhu H, Li X, Li J, Fan H, Wu Z, Guo Z, Hu Y, Wu S, Yu X, Xu C, Wang Z. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma. Tumour Biol 2015;36:2427-35. [PMID: 25431261 DOI: 10.1007/s13277-014-2853-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
33 Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008;3:228-31. [PMID: 18782081 DOI: 10.2174/157488708785700267] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
34 Wolfe TD, Pillai SP, Hildreth BE 3rd, Lanigan LG, Martin CK, Werbeck JL, Rosol TJ. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis 2011;28:377-89. [PMID: 21374084 DOI: 10.1007/s10585-011-9377-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
35 Cai X, Zhang H, Tong D, Tan Z, Han D, Ji F, Hu W. Corosolic acid triggers mitochondria and caspase-dependent apoptotic cell death in osteosarcoma MG-63 cells. Phytother Res 2011;25:1354-61. [PMID: 21341336 DOI: 10.1002/ptr.3422] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
36 Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, Heymann D, Rédini F, Trichet V. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther 2010;17:387-97. [DOI: 10.1038/cgt.2009.89] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
37 Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther 2020;20:415-28. [PMID: 32379504 DOI: 10.1080/14737140.2020.1760848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Senturk JC, Bohlman S, Manfredi JJ. Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. Oncogene 2017;36:6085-96. [PMID: 28692049 DOI: 10.1038/onc.2017.229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
39 Liu G, Sheng Y, Zhang M, Sun D. A polysaccharide from the leaves of Aralia elata induces apoptosis in U-2 OS cells via mitochondrial-dependent pathway. International Journal of Biological Macromolecules 2016;93:418-25. [DOI: 10.1016/j.ijbiomac.2016.08.067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
40 Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010;15:615-34. [PMID: 20690888 DOI: 10.1517/14728214.2010.505603] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
41 Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y, Toledo SR. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum Pathol 2012;43:994-1002. [PMID: 22154052 DOI: 10.1016/j.humpath.2011.08.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
42 Aina V, Malavasi G, Magistris C, Cerrato G, Martra G, Viscardi G, Menabue L, Lusvardi G. Conjugation of amino-bioactive glasses with 5-aminofluorescein as probe molecule for the development of pH sensitive stimuli-responsive biomaterials. J Mater Sci Mater Med 2014;25:2243-53. [PMID: 24722810 DOI: 10.1007/s10856-014-5206-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
43 He F, Fang L, Yin Q. miR-363 acts as a tumor suppressor in osteosarcoma cells by inhibiting PDZD2. Oncol Rep 2019;41:2729-38. [PMID: 30896877 DOI: 10.3892/or.2019.7078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
44 Hao S, Zhu J, Zhang X, Qiu J, Xuan Q, Ye L. Comprehensive Analysis of Aerobic Exercise-Related Genes Identifies CDCA4 That Promotes the Progression of Osteosarcoma. Front Genet 2021;12:637755. [PMID: 33613651 DOI: 10.3389/fgene.2021.637755] [Reference Citation Analysis]
45 Luo X, Liu X, Tao Q, Yao C, Wang F, Gu Z, Li F, Yu X, Zhang B, Fan H, Dai M, Nie T. Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model. Oncol Lett 2020;20:1400-8. [PMID: 32724382 DOI: 10.3892/ol.2020.11656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Deng R, Zhang J, Chen J. lncRNA SNHG1 negatively regulates miRNA‑101‑3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma. Int J Mol Med 2019;43:1157-66. [PMID: 30592267 DOI: 10.3892/ijmm.2018.4039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
47 Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016;16:543-56. [PMID: 26999418 DOI: 10.1586/14737140.2016.1168697] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 15.2] [Reference Citation Analysis]
48 Qu Y, Pan S, Kang M, Dong R, Zhao J. MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1. Tumour Biol 2016;37:5275-84. [PMID: 26561465 DOI: 10.1007/s13277-015-4389-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
49 Zhao J, Xu H, He M, Wang Z, Wu Y. Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis. Biomed Res Int 2014;2014:396947. [PMID: 25136583 DOI: 10.1155/2014/396947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
50 Miot-Noirault E, Gouin F, Dauplat MM, Heymann D, Chezal JM, Redini F. Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma. Cancer Biother Radiopharm 2012;27:96-103. [PMID: 22217151 DOI: 10.1089/cbr.2011.1059] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
52 Macsai CE, Foster BK, Xian CJ. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol. 2008;215:578-587. [PMID: 18247365 DOI: 10.1002/jcp.21342] [Cited by in Crossref: 113] [Cited by in F6Publishing: 109] [Article Influence: 8.1] [Reference Citation Analysis]
53 Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget 2014;5:7805-19. [PMID: 25138053 DOI: 10.18632/oncotarget.2308] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
54 Yu S, Shao F, Liu H, Liu Q. A five metastasis-related long noncoding RNA risk signature for osteosarcoma survival prediction. BMC Med Genomics 2021;14:124. [PMID: 33964903 DOI: 10.1186/s12920-021-00972-5] [Reference Citation Analysis]
55 Nada OH, Ahmed NS, Abou Gabal HH. Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 2014;9:72. [PMID: 24667142 DOI: 10.1186/1746-1596-9-72] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
56 Mittal N, Kent PM, Ording J. Metastatic and recurrent bone primary bone cancers. Curr Probl Cancer 2013;37:215-24. [PMID: 24238587 DOI: 10.1016/j.currproblcancer.2013.07.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Huang Y, Yao J, Zhu B, Zhang J, Sun T. Mitogen-activated protein kinase 7 promotes cell proliferation, migration and invasion in SOSP-M human osteosarcoma cell line. Tumori 2017;103:483-8. [PMID: 26350187 DOI: 10.5301/tj.5000399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
58 Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TJ, Schellens JH. Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report. Tumori 2011;97:109-14. [DOI: 10.1177/030089161109700119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
59 Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang L, Gao JQ, Yu LS, Zhu DF, Yang B, He QJ, Ying MD. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin. 2019;40:546-555. [PMID: 29930276 DOI: 10.1038/s41401-018-0050-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
60 Gong X, Li W, Dong L, Qu F. CircUBAP2 promotes SEMA6D expression to enhance the cisplatin resistance in osteosarcoma through sponging miR-506-3p by activating Wnt/β-catenin signaling pathway. J Mol Histol 2020;51:329-40. [PMID: 32472335 DOI: 10.1007/s10735-020-09883-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]